Author

D. Ayyildiz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

J. Drost· 2 shared A. Balwierz· 1 shared A. Fumagalli· 1 shared A. van Oudenaarden· 1 shared E. de Wit· 1 shared E. W. Hoving· 1 shared F. Morales-Rodriguez· 1 shared H. Teunissen· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Drost

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying translocation RCC.

M. Ganpat, F. Morales-Rodriguez, N. Pham, P. Lijnzaad, T. de Souza, S. Derakhshan, A. Fumagalli, P. Zeller, A. Balwierz, D. Ayyildiz, M. M. van den Heuvel-Eibrink, R. R. de Krijger, A. van Oudenaarden, T. Margaritis, S. M. Chuva de Sousa Lopes, J. Drost

This study creates an engineered tumor organoid model of tRCC using SFPQ-TFE3 fusion expression, revealing epithelium-to-mesenchymal differentiation and Wnt signaling involvement in tumor transformation.

bioRxiv · Sep 1, 2023 · PreprintCancer Biology

SMARCB1 loss creates patient-specific MYC topologies that drive malignant rhabdoid tumor growth

N. Q. Liu, I. Paassen, L. Custers, H. Teunissen, D. Ayyildiz, J. He, E. W. Hoving, E. de Wit, J. Drost

This study shows that SMARCB1 loss leads to patient-specific MYC enhancer looping, driving MRT growth through epigenetic reprogramming.

bioRxiv · Nov 21, 2022 · PreprintCancer Biology